JP2014532623A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532623A5
JP2014532623A5 JP2014537142A JP2014537142A JP2014532623A5 JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5 JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014537142 A JP2014537142 A JP 2014537142A JP 2014532623 A5 JP2014532623 A5 JP 2014532623A5
Authority
JP
Japan
Prior art keywords
composition
liposomes
lyophilization
reconstitution
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537142A
Other languages
English (en)
Japanese (ja)
Other versions
JP6133308B2 (ja
JP2014532623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/060293 external-priority patent/WO2013059133A1/en
Publication of JP2014532623A publication Critical patent/JP2014532623A/ja
Publication of JP2014532623A5 publication Critical patent/JP2014532623A5/ja
Application granted granted Critical
Publication of JP6133308B2 publication Critical patent/JP6133308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537142A 2011-10-21 2012-10-15 凍結乾燥リポソーム Active JP6133308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
US61/550,047 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074348A Division JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム

Publications (3)

Publication Number Publication Date
JP2014532623A JP2014532623A (ja) 2014-12-08
JP2014532623A5 true JP2014532623A5 (cg-RX-API-DMAC7.html) 2015-10-15
JP6133308B2 JP6133308B2 (ja) 2017-05-24

Family

ID=48141268

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014537142A Active JP6133308B2 (ja) 2011-10-21 2012-10-15 凍結乾燥リポソーム
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017074348A Active JP6359717B2 (ja) 2011-10-21 2017-04-04 凍結乾燥リポソーム
JP2018095127A Active JP6592556B2 (ja) 2011-10-21 2018-05-17 凍結乾燥リポソーム
JP2019172314A Pending JP2020007367A (ja) 2011-10-21 2019-09-20 凍結乾燥リポソーム
JP2021196626A Active JP7476161B2 (ja) 2011-10-21 2021-12-03 凍結乾燥リポソーム
JP2024000732A Pending JP2024045183A (ja) 2011-10-21 2024-01-05 凍結乾燥リポソーム

Country Status (22)

Country Link
US (5) US10028912B2 (cg-RX-API-DMAC7.html)
EP (2) EP2768484B1 (cg-RX-API-DMAC7.html)
JP (6) JP6133308B2 (cg-RX-API-DMAC7.html)
KR (5) KR102284689B1 (cg-RX-API-DMAC7.html)
CN (2) CN104114156A (cg-RX-API-DMAC7.html)
AU (1) AU2012326370C9 (cg-RX-API-DMAC7.html)
BR (1) BR112014009305B1 (cg-RX-API-DMAC7.html)
CA (1) CA2852777C (cg-RX-API-DMAC7.html)
DK (1) DK2768484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2750368T3 (cg-RX-API-DMAC7.html)
FR (1) FR19C1063I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20191683T1 (cg-RX-API-DMAC7.html)
HU (2) HUE045978T2 (cg-RX-API-DMAC7.html)
IL (1) IL232161B (cg-RX-API-DMAC7.html)
LU (1) LUC00135I2 (cg-RX-API-DMAC7.html)
NL (1) NL301016I2 (cg-RX-API-DMAC7.html)
NO (1) NO2019041I1 (cg-RX-API-DMAC7.html)
PL (1) PL2768484T3 (cg-RX-API-DMAC7.html)
PT (1) PT2768484T (cg-RX-API-DMAC7.html)
RU (1) RU2648753C2 (cg-RX-API-DMAC7.html)
SI (1) SI2768484T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013059133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648753C2 (ru) * 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
JP6858698B2 (ja) 2014-08-28 2021-04-21 ザ ジェネラル ホスピタル コーポレイション 注射可能なスラリーならびにその製造方法および使用方法
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
EP3283045B1 (en) * 2015-04-13 2021-02-17 Fountain Technologies International, LLC One-step method for production of ultra-small lipid structures
RS61607B1 (sr) 2015-07-22 2021-04-29 Nitto Denko Corp Kompozicije i postupci za nanočestične liofilne oblike
CN115414376A (zh) * 2015-11-11 2022-12-02 塞拉特药物股份有限公司 选择白血病对象的治疗方案的分析和方法
KR102740583B1 (ko) 2016-02-26 2024-12-11 더 제너럴 하스피탈 코포레이션 의료용 빙류 슬러리 제조 및 전달 시스템 및 방법
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3651733A4 (en) * 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING USING LIPID VESICLE PARTICLES OF DEFINED SIZE, AND USES THEREOF
CA3114002A1 (en) 2018-09-25 2020-04-02 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3144443A1 (en) * 2019-06-28 2020-12-30 Moleculin Biotech, Inc. Method of reconstituting liposomal annamycin
EP4003295A1 (en) * 2019-07-24 2022-06-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术(石家庄)有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
WO1986003938A1 (en) 1985-01-11 1986-07-17 The Regents Of The University Of California Method for preserving liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
ATE107502T1 (de) * 1988-10-05 1994-07-15 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
ATE237362T1 (de) 1996-02-19 2003-05-15 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
CN1156269C (zh) 1999-07-16 2004-07-07 阿尔萨公司 抗冻/融损害的脂质体组合物
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
IL161187A0 (en) 2001-10-03 2004-08-31 Celator Technologies Inc Liposome compositions containing metal ions and therapeutic agents
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ES2290333T3 (es) 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
JP2006522026A (ja) * 2003-04-02 2006-09-28 セレーター ファーマスーティカルズ、インク. カンプトセシンとフルオロピリミジンとを組み合わせた組成物
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
US7893338B2 (en) 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20080107722A1 (en) 2004-11-18 2008-05-08 Paul Tardi Method For Loading Multiple Agents Into Delivery Vehicles
CA2628015C (en) 2005-10-25 2016-02-23 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
CA2678332C (en) * 2007-02-16 2015-06-02 Celator Pharmaceuticals, Inc. Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
US20120003294A1 (en) 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
US20110223241A1 (en) 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
HRP20150911T1 (hr) 2009-12-03 2015-10-23 Jiangsu Hengrui Medicine Co., Ltd. Liposom irinotekana ili njegovog hidroklorida te postupak njegove pripreme
US20130052259A1 (en) * 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
RU2648753C2 (ru) * 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы

Similar Documents

Publication Publication Date Title
JP2014532623A5 (cg-RX-API-DMAC7.html)
JP2020007367A5 (cg-RX-API-DMAC7.html)
JP2024045183A5 (cg-RX-API-DMAC7.html)
Shao et al. Biomimetic diselenide‐bridged mesoporous organosilica nanoparticles as an X‐ray‐responsive biodegradable carrier for chemo‐immunotherapy
Jin et al. Nanoparticle‐mediated delivery of inhaled immunotherapeutics for treating lung metastasis
RU2014120475A (ru) Лиофилизированные липосомы
van der Heijden et al. Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer
US12364664B2 (en) Lyophilized compositions comprising arsenic
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
RU2018110333A (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
NZ701915A (en) High-concentration monoclonal antibody formulations
NZ707328A (en) Virus-containing formulation and use thereof
JP2011251975A5 (cg-RX-API-DMAC7.html)
JP2013511557A5 (cg-RX-API-DMAC7.html)
KR20200029636A (ko) 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
Zhao et al. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review
WO2012107865A3 (en) Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
CN108495619A (zh) 棘霉素制剂及其制备方法和使用方法
JP2019521179A5 (cg-RX-API-DMAC7.html)
AU2021270347A1 (en) Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
Rampersaud et al. Hyperthermia as a treatment for bladder cancer
AR094770A1 (es) Composición masticable para administración oral y proceso para preparar la misma
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
JP2015526463A5 (cg-RX-API-DMAC7.html)
BR112016006989A2 (pt) Formulação imunogênica, uso de uma formulação imunogênica e vacina contra hmpv